123 related articles for article (PubMed ID: 86208)
1. Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
Caruso TP; Takemori AE; Larson DL; Portoghese PS
Science; 1979 Apr; 204(4390):316-8. PubMed ID: 86208
[TBL] [Abstract][Full Text] [Related]
2. Morphine analgesia after intrathecal administration of a narcotic agonist, chloroxymorphamine and antagonist, chlornaltrexamine.
Larson AA; Armstrong MJ
Eur J Pharmacol; 1980 Nov; 68(1):25-31. PubMed ID: 6161013
[No Abstract] [Full Text] [Related]
3. Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
Caruso TP; Larson DL; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1980 Jun; 213(3):539-44. PubMed ID: 6162947
[TBL] [Abstract][Full Text] [Related]
4. 6beta-[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan(chlornaltrexamine) a potent opioid receptor alkylating agent with ultralong narcotic antagonist actitivty.
Portoghese PS; Larson DL; Jiang JB; Takemori AE; Caruso TP
J Med Chem; 1978 Jul; 21(7):598-9. PubMed ID: 209185
[No Abstract] [Full Text] [Related]
5. Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation.
Koman A; Einarsson M; Terenius L
Naunyn Schmiedebergs Arch Pharmacol; 1985 Dec; 331(4):355-8. PubMed ID: 2419770
[TBL] [Abstract][Full Text] [Related]
6. 10-Ketonaltrexone and 10-ketooxymorphone.
Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
[TBL] [Abstract][Full Text] [Related]
7. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.
Portoghese PS; Larson DL; Sayre LM; Fries DS; Takemori AE
J Med Chem; 1980 Mar; 23(3):233-4. PubMed ID: 6245210
[No Abstract] [Full Text] [Related]
8. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
Fang X; Larson DL; Portoghese PS
J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
[TBL] [Abstract][Full Text] [Related]
9. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
Hahn EF; Nishimura S; Goodman RR; Pasternak GW
J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
Portoghese PS; Larson DL; Jiang JB; Caruso TP; Takemori AE
J Med Chem; 1979 Feb; 22(2):168-73. PubMed ID: 218009
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist and antagonist activities of monofunctional nitrogen mustard analogues of beta-chlornaltrexamine.
Schoenecker JW; Takemori AE; Portoghese PS
J Med Chem; 1987 May; 30(5):933-5. PubMed ID: 3033246
[TBL] [Abstract][Full Text] [Related]
12. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
Takemori AE; Larson DL; Portoghese PS
Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637
[TBL] [Abstract][Full Text] [Related]
13. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand.
Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ
J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395
[TBL] [Abstract][Full Text] [Related]
14. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
Hahn EF; Carroll-Buatti M; Pasternak GW
J Neurosci; 1982 May; 2(5):572-6. PubMed ID: 6176696
[TBL] [Abstract][Full Text] [Related]
15. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
Schmidhammer H; Leander JD; Mayer-Valkanover K; Nussbaumer C; Schmidt C; Schoepp DD; Schratz A; Walla-Kugler M
Prog Clin Biol Res; 1990; 328():41-4. PubMed ID: 2154800
[No Abstract] [Full Text] [Related]
16. Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
Galetta S; Hahn EF; Nishimura S; Pasternak GW
Life Sci; 1987 Aug; 41(6):783-7. PubMed ID: 2441221
[TBL] [Abstract][Full Text] [Related]
17. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.
Pasternak GW; Hahn EF
J Med Chem; 1980 Jun; 23(6):674-6. PubMed ID: 6156240
[TBL] [Abstract][Full Text] [Related]
18. Opioid agonist and antagonist bivalent ligands as receptor probes.
Portoghese PS; Ronsisvalle G; Larson DL; Yim CB; Sayre LM; Takemori AE
Life Sci; 1982 Sep 20-27; 31(12-13):1283-6. PubMed ID: 6292615
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of gastrointestinal transit by morphine and FK 33-824 in the rat and comparative narcotic antagonist properties of naloxone and its N-methyl quaternary analog.
Manara L; Bianchi G; Fiocchi R; Notarnicola A; Peracchia F; Tavani A
Life Sci; 1982 Sep 20-27; 31(12-13):1271-4. PubMed ID: 6183550
[TBL] [Abstract][Full Text] [Related]
20. Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
Botros S; Lipkowski AW; Larson DL; Stark PA; Takemori AE; Portoghese PS
J Med Chem; 1989 Sep; 32(9):2068-71. PubMed ID: 2475628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
